Skip to main content
. Author manuscript; available in PMC: 2019 Nov 25.
Published in final edited form as: Nat Rev Nephrol. 2019 Mar;15(3):129–143. doi: 10.1038/s41581-018-0107-2

Table 5.

Novel therapeutic agents that target complement activity

Drug Target Mechanism Clinical trial
number
ACH-0144471 Factor D Prevents formation of C3 and C5 convertases , ,
LNP023 Factor B Prevents formation of C3 and C5 convertases Not yet registered
APL2 C3 Prevents formation of C3 and C5 convertases
AMY-101 C3 Prevents formation of C3 and C5 convertases
OMS721 MASP-2 Blocks initiation of lectin pathway
Eculizumab C5 Blocks progression of terminal pathway Off-label use
Avacopan C5aR1 Blocks anaphylatoxin formation (C3a, C4a and/or C5a)

No clinical trials of drugs that enhance complement regulation are currently ongoing in patients with C3 glomerulopathy.